Antitope to Present at bioLOGIC Europe 2008 in Geneva on 18th Sept 2008

Dr. Matthew Baker, CEO of Antitope, will chair a conference session entitled "Biological Product Development" at this years biologic 2008 in Geneva. The session will include discussion concerning "Adding Value to Biologics Development", "Dealing with Immunogenicity and Achieving Comparability" and "Quality by Design in Biologics Process Development". Dr Baker will also be presenting a paper entitled "immunogenicity: understanding the implications for product development and designing an effective risk assessment strategy",

The presentation will explain why immunogenicity of biological medicines is such a problem, outline strategies and tools for assessing the potential immunogenicity of a biological medicine and give an expert view on how to avoid the main pitfalls and failures in immunogenicity assessment.

For more information, visit the conference website at http://www.terrapinn.com/2008/bio_eur/index.stm